The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Shares of Merck & Co. Inc. MRK shed 2.76% to $97.92 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.00% to 5,996.66 and ...

Medical industry giants Eli Lilly and Merck will collaborate with Purdue through a new institute, which aims to advance ...

Co Inc (NYSE:MRK) shares, reducing the pharmaceutical giant's price target from $130.00 to $122.00 while reaffirming a Buy rating on the stock. The revision by Guggenheim analyst is primarily due to ...

Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.

Organon has faced significant price volatility and underperformance since its spin-off from Merck. Check out why I recommend ...

The Dow’s Friday morning rally included nearly every stock in the blue-chip index—at least the ones without an ampersand in their names. Of the three stocks in the index that were trading lower in ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

Lotte Biologics has ambitious plans for its antibody-drug conjugate and contract development and manufacturing organization ...